Evarrest

RSS

Withdrawn

This medicine's authorisation has been withdrawn

human fibrinogen / human thrombin
MedicineHumanWithdrawn

Greek is available via eTranslation, the European Commission's machine translation service.

Translate to Greek | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 15 November 2017, the European Commission withdrew the marketing authorisation for Evarrest (human fibrinogen / human thrombin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Omrix Biopharmaceuticals N. V., which notified the European Commission of its decision to permanently discontinue the marketing of the product in the EU for commercial reasons. 

Evarrest was granted marketing authorisation in the EU on 25 September 2013 for the treatment of haemostasis and as an adjunct to haemostasis in bleeding.

The European Public Assessment Report (EPAR) for Evarrest is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (597.14 KB - PDF)

Προβολή

español (ES) (515.07 KB - PDF)

Προβολή

čeština (CS) (578.52 KB - PDF)

Προβολή

dansk (DA) (518.89 KB - PDF)

Προβολή

Deutsch (DE) (516.28 KB - PDF)

Προβολή

eesti (ET) (518.26 KB - PDF)

Προβολή

ελληνικά (EL) (600.8 KB - PDF)

Προβολή

français (FR) (518 KB - PDF)

Προβολή

hrvatski (HR) (535.13 KB - PDF)

Προβολή

italiano (IT) (514.66 KB - PDF)

Προβολή

latviešu (LV) (593.61 KB - PDF)

Προβολή

lietuvių (LT) (538.4 KB - PDF)

Προβολή

magyar (HU) (571.9 KB - PDF)

Προβολή

Malti (MT) (577.35 KB - PDF)

Προβολή

Nederlands (NL) (514.67 KB - PDF)

Προβολή

polski (PL) (576.8 KB - PDF)

Προβολή

português (PT) (536.9 KB - PDF)

Προβολή

română (RO) (1020.06 KB - PDF)

Προβολή

slovenčina (SK) (100.5 KB - PDF)

Προβολή

slovenščina (SL) (567.85 KB - PDF)

Προβολή

suomi (FI) (513.9 KB - PDF)

Προβολή

svenska (SV) (514.56 KB - PDF)

Προβολή

Product information

български (BG) (1.55 MB - PDF)

Προβολή

español (ES) (896.44 KB - PDF)

Προβολή

čeština (CS) (1.51 MB - PDF)

Προβολή

dansk (DA) (813.54 KB - PDF)

Προβολή

Deutsch (DE) (845.01 KB - PDF)

Προβολή

eesti (ET) (787.41 KB - PDF)

Προβολή

ελληνικά (EL) (1.55 MB - PDF)

Προβολή

français (FR) (818.58 KB - PDF)

Προβολή

hrvatski (HR) (898.08 KB - PDF)

Προβολή

italiano (IT) (816.34 KB - PDF)

Προβολή

latviešu (LV) (1.31 MB - PDF)

Προβολή

lietuvių (LT) (910.1 KB - PDF)

Προβολή

magyar (HU) (1.15 MB - PDF)

Προβολή

Malti (MT) (1.31 MB - PDF)

Προβολή

Nederlands (NL) (827.81 KB - PDF)

Προβολή

polski (PL) (1.32 MB - PDF)

Προβολή

português (PT) (818.67 KB - PDF)

Προβολή

română (RO) (934.43 KB - PDF)

Προβολή

slovenčina (SK) (1.32 MB - PDF)

Προβολή

slovenščina (SL) (1.25 MB - PDF)

Προβολή

suomi (FI) (923.42 KB - PDF)

Προβολή

svenska (SV) (864.7 KB - PDF)

Προβολή

Íslenska (IS) (877.78 KB - PDF)

Προβολή

norsk (NO) (860 KB - PDF)

Προβολή
Latest procedure affecting product information:II/0027/G
15/11/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (496.48 KB - PDF)

Προβολή

español (ES) (460.12 KB - PDF)

Προβολή

čeština (CS) (486.03 KB - PDF)

Προβολή

dansk (DA) (460.06 KB - PDF)

Προβολή

Deutsch (DE) (459.93 KB - PDF)

Προβολή

eesti (ET) (459.94 KB - PDF)

Προβολή

ελληνικά (EL) (496.65 KB - PDF)

Προβολή

français (FR) (459.86 KB - PDF)

Προβολή

hrvatski (HR) (472.28 KB - PDF)

Προβολή

italiano (IT) (459.91 KB - PDF)

Προβολή

latviešu (LV) (489.48 KB - PDF)

Προβολή

lietuvių (LT) (474.86 KB - PDF)

Προβολή

magyar (HU) (484.42 KB - PDF)

Προβολή

Malti (MT) (490.05 KB - PDF)

Προβολή

Nederlands (NL) (459.69 KB - PDF)

Προβολή

polski (PL) (489.07 KB - PDF)

Προβολή

português (PT) (459.81 KB - PDF)

Προβολή

română (RO) (930.92 KB - PDF)

Προβολή

slovenčina (SK) (29.59 KB - PDF)

Προβολή

slovenščina (SL) (483.95 KB - PDF)

Προβολή

suomi (FI) (460.2 KB - PDF)

Προβολή

svenska (SV) (459.88 KB - PDF)

Προβολή

Íslenska (IS) (460 KB - PDF)

Προβολή

norsk (NO) (459.61 KB - PDF)

Προβολή

Product details

Name of medicine
Evarrest
Active substance
  • human fibrinogen
  • human thrombin
International non-proprietary name (INN) or common name
  • human fibrinogen
  • human thrombin
Therapeutic area (MeSH)
Hemostasis
Anatomical therapeutic chemical (ATC) code
B02BC30

Pharmacotherapeutic group

Local hemostatics

Therapeutic indication

Supportive treatment in adult surgery where standard surgical techniques are insufficient (see section 5.1):

- for improvement of haemostasis.

Authorisation details

EMA product number
EMEA/H/C/002515
Marketing authorisation holder
Omrix Biopharmaceuticals N. V.

Leonardo Da Vinci Laan 15
1831 Diegem
Belgium

Marketing authorisation issued
25/09/2013
Withdrawal of marketing authorisation
15/11/2017
Revision
4

Assessment history

This page was last updated on

Share this page